Periodic Reporting for period 1 - ENZYBIOTX (Upgrading business potential of Enzybiotx)
Okres sprawozdawczy: 2022-06-01 do 2023-01-31
Since the discovery of penicillin people were living in justified confidence that available antibiotics can cure any bacterial infections. Emerging antibiotic resistance was usually overcome by treatment with new generation of antibiotics, but during last decades bacteria are clearly winning this race. Overuse of antibiotics, particularly in agriculture, and lack of investments in discovery of new antibiotics lead us to situation when increasing number of bacterial infections cannot be cured due to lack of effective remedy. Antibiotic resistance surveillance revealed rising antibiotic resistance around the world. WHO predicts that if no appropriate actions are taken by 2050 antibiotic resistance will be responsible even for 10 mln deaths every year. To address this urgent medical need new antibiotics and alternative methods of combating antibiotic resistant bacteria are needed. One of the new approaches which is getting more and more interests among academic and industrial research groups are enzybiotics, bacteriolytic enzymes that in a very effective and selective way eliminate bacteria, including antibiotic resistant strains, at the same time displaying very low resistance prevalence. Enzybiotx provides a deep-tech platform for tailor made-enzybiotics targeting specific bacteria. Our company has developed the platform for design and generation of new enzybiotcs to target pathogenic bacteria of interest as an answer to the need of alternative antimicrobials development. The company in collaboration with potential clients is able to prepare tailor-made enzybiotics which target pathogens and in collaboration with the client, perform all tests needed to adjust enzyme’s properties to be able to introduce them to the final products.
The founders of the company are experienced academics who have gathered unique expertise in isolation and characterisation of new enzybiotics.
The founders of the company are experienced academics who have gathered unique expertise in isolation and characterisation of new enzybiotics.
Thanks to the funding, Enzybiotx has carried out the following activities:
a) An extensive market, regulatory and growth strategy was ordered from a consultancy company experienced in biotech and med-tech markets. The company has also carried out a very detailed comparative analysis of various licensing agreements from all over the world to determine best strategy for Enzybiotx in terms on fees (upfront and royalty) as well as additional terms and conditions of such agreements. The analysis covered two markets, which Enzybiotx has identified as the most promising ones – dermocosmetics and wound care. The analysis covered respective use cases on different markets and geographic areas, potential new use cases associated with various skin diseases, model of cooperation with established market players as well as potential regulatory pathway to market authorization with comparative analysis with our closes competitors,
b) An extensive market analysis was also purchased from a specialized entity
c) A detailed financial plan and financial model to simulate Enzybiotx’ future profitability and return from investment,
d) Freedom to Operate analysis ordered,
e) Secured the IP protection for both enzymes,
f) Product validation – tests comparing the enzyme characteristics with the enzyme of our direct competitor, especially the effectiveness of AuresinePLUS. Results of various tests were compared to that of our competition and AuresinePLUS turned to be at least as effective with one large advantage over their enzyme – AuresinePLUS is effective in a much wider range of temperatures,
g) Mentoring and coaching – aimed at helping the female founder with expanding our network, learning how to approach large corporate players, fine-tune pitching, gain visibility on the market and attracting further funding,
h) Expansion of the official webpage – new sections were added.
a) An extensive market, regulatory and growth strategy was ordered from a consultancy company experienced in biotech and med-tech markets. The company has also carried out a very detailed comparative analysis of various licensing agreements from all over the world to determine best strategy for Enzybiotx in terms on fees (upfront and royalty) as well as additional terms and conditions of such agreements. The analysis covered two markets, which Enzybiotx has identified as the most promising ones – dermocosmetics and wound care. The analysis covered respective use cases on different markets and geographic areas, potential new use cases associated with various skin diseases, model of cooperation with established market players as well as potential regulatory pathway to market authorization with comparative analysis with our closes competitors,
b) An extensive market analysis was also purchased from a specialized entity
c) A detailed financial plan and financial model to simulate Enzybiotx’ future profitability and return from investment,
d) Freedom to Operate analysis ordered,
e) Secured the IP protection for both enzymes,
f) Product validation – tests comparing the enzyme characteristics with the enzyme of our direct competitor, especially the effectiveness of AuresinePLUS. Results of various tests were compared to that of our competition and AuresinePLUS turned to be at least as effective with one large advantage over their enzyme – AuresinePLUS is effective in a much wider range of temperatures,
g) Mentoring and coaching – aimed at helping the female founder with expanding our network, learning how to approach large corporate players, fine-tune pitching, gain visibility on the market and attracting further funding,
h) Expansion of the official webpage – new sections were added.